Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial
Sponsor: Biomedical Primate Research Centre
This PHASE1 trial investigates Plasmodium Falciparum Malaria and is currently completed. Biomedical Primate Research Centre leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Sep 2023 [monthly]
Completed PHASE1
-
Mar 2022 — Feb 2023 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Primate Research Centre
- European Vaccine Initiative
- GlaxoSmithKline
- Radboud University Medical Center
- Seppic
For direct contact, visit the study record on ClinicalTrials.gov .